Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Heart Failure | 87 | 2024 | 11837 | 6.940 |
Why?
|
Stroke Volume | 50 | 2024 | 5595 | 4.840 |
Why?
|
Galectin 3 | 10 | 2019 | 238 | 2.810 |
Why?
|
Ventricular Function, Left | 24 | 2024 | 3930 | 2.430 |
Why?
|
Exercise Test | 18 | 2024 | 2185 | 2.410 |
Why?
|
Exercise Tolerance | 14 | 2023 | 841 | 2.390 |
Why?
|
Hypertension, Pulmonary | 9 | 2023 | 1604 | 2.170 |
Why?
|
Cardiovascular Diseases | 37 | 2024 | 15647 | 2.100 |
Why?
|
Obesity | 21 | 2024 | 13085 | 1.740 |
Why?
|
Atrial Fibrillation | 12 | 2024 | 5185 | 1.540 |
Why?
|
Dyspnea | 8 | 2024 | 1351 | 1.420 |
Why?
|
Pulmonary Wedge Pressure | 6 | 2024 | 277 | 1.420 |
Why?
|
Ventricular Dysfunction, Right | 3 | 2023 | 645 | 1.410 |
Why?
|
Growth Differentiation Factor 15 | 6 | 2014 | 198 | 1.370 |
Why?
|
Receptors, Cell Surface | 8 | 2015 | 2815 | 1.140 |
Why?
|
Insulin Resistance | 9 | 2023 | 3988 | 0.980 |
Why?
|
Atherosclerosis | 6 | 2023 | 3418 | 0.910 |
Why?
|
Ventricular Dysfunction, Left | 5 | 2024 | 2136 | 0.870 |
Why?
|
Middle Aged | 100 | 2024 | 223083 | 0.870 |
Why?
|
Risk Factors | 61 | 2024 | 74857 | 0.840 |
Why?
|
Hemodynamics | 8 | 2023 | 4188 | 0.830 |
Why?
|
Blood Proteins | 7 | 2022 | 1186 | 0.830 |
Why?
|
Inflammation Mediators | 2 | 2022 | 1890 | 0.820 |
Why?
|
Metabolome | 8 | 2020 | 1005 | 0.800 |
Why?
|
Heart Ventricles | 6 | 2022 | 3833 | 0.790 |
Why?
|
Humans | 178 | 2024 | 766117 | 0.790 |
Why?
|
Sex Factors | 13 | 2024 | 10614 | 0.780 |
Why?
|
Female | 118 | 2024 | 396233 | 0.730 |
Why?
|
Proteomics | 7 | 2023 | 3907 | 0.730 |
Why?
|
Hypertrophy, Left Ventricular | 5 | 2021 | 855 | 0.710 |
Why?
|
Male | 107 | 2024 | 363935 | 0.700 |
Why?
|
Hypertension | 6 | 2023 | 8616 | 0.700 |
Why?
|
Ventricular Function, Right | 4 | 2023 | 629 | 0.690 |
Why?
|
Pulmonary Artery | 4 | 2023 | 1938 | 0.690 |
Why?
|
C-Reactive Protein | 8 | 2023 | 3853 | 0.680 |
Why?
|
Incidence | 25 | 2023 | 21513 | 0.680 |
Why?
|
Prognosis | 26 | 2024 | 29912 | 0.670 |
Why?
|
Blood Sedimentation | 1 | 2020 | 234 | 0.670 |
Why?
|
Heart Rate | 4 | 2020 | 4204 | 0.660 |
Why?
|
Systole | 5 | 2020 | 935 | 0.640 |
Why?
|
Myocardium | 6 | 2020 | 4766 | 0.630 |
Why?
|
Infertility | 2 | 2023 | 655 | 0.630 |
Why?
|
Natriuretic Peptide, Brain | 9 | 2024 | 1735 | 0.620 |
Why?
|
Adipokines | 2 | 2020 | 308 | 0.620 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2020 | 427 | 0.620 |
Why?
|
Respiratory Function Tests | 2 | 2021 | 1692 | 0.610 |
Why?
|
Aged | 64 | 2024 | 171219 | 0.610 |
Why?
|
Oxygen Consumption | 4 | 2024 | 1872 | 0.610 |
Why?
|
Dyslipidemias | 2 | 2016 | 871 | 0.610 |
Why?
|
Phenotype | 6 | 2023 | 16716 | 0.600 |
Why?
|
Troponin | 3 | 2023 | 532 | 0.600 |
Why?
|
Body Mass Index | 14 | 2024 | 13046 | 0.590 |
Why?
|
Extracellular Matrix Proteins | 1 | 2021 | 833 | 0.560 |
Why?
|
Hospitalization | 10 | 2024 | 10811 | 0.560 |
Why?
|
Calcium-Binding Proteins | 1 | 2021 | 1077 | 0.550 |
Why?
|
Sex Characteristics | 3 | 2022 | 2646 | 0.540 |
Why?
|
Inflammation | 6 | 2023 | 10860 | 0.520 |
Why?
|
Albuminuria | 3 | 2017 | 659 | 0.520 |
Why?
|
Heptanoic Acids | 3 | 2012 | 344 | 0.510 |
Why?
|
Heart Diseases | 3 | 2023 | 2818 | 0.510 |
Why?
|
Cardiovascular System | 2 | 2023 | 838 | 0.510 |
Why?
|
Adult | 60 | 2024 | 223139 | 0.500 |
Why?
|
Renal Insufficiency, Chronic | 4 | 2023 | 2306 | 0.480 |
Why?
|
Troponin I | 3 | 2014 | 656 | 0.470 |
Why?
|
Proportional Hazards Models | 13 | 2021 | 12529 | 0.470 |
Why?
|
Electrocardiography | 5 | 2024 | 6409 | 0.460 |
Why?
|
Cardiomyopathies | 5 | 2023 | 2068 | 0.450 |
Why?
|
Longitudinal Studies | 14 | 2023 | 14747 | 0.450 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2017 | 3249 | 0.440 |
Why?
|
Coronary Disease | 6 | 2014 | 5919 | 0.440 |
Why?
|
Lung | 6 | 2022 | 10063 | 0.440 |
Why?
|
Brachial Artery | 3 | 2012 | 374 | 0.440 |
Why?
|
Phosphodiesterase 5 Inhibitors | 1 | 2014 | 103 | 0.440 |
Why?
|
Stroke | 8 | 2024 | 9748 | 0.430 |
Why?
|
Risk Assessment | 13 | 2024 | 24276 | 0.420 |
Why?
|
Myocardial Infarction | 8 | 2023 | 11509 | 0.410 |
Why?
|
Diabetes Mellitus | 6 | 2023 | 5889 | 0.410 |
Why?
|
Obesity, Abdominal | 1 | 2015 | 371 | 0.400 |
Why?
|
Prospective Studies | 23 | 2023 | 54812 | 0.400 |
Why?
|
Carbolines | 1 | 2014 | 288 | 0.400 |
Why?
|
Resistin | 2 | 2023 | 174 | 0.400 |
Why?
|
Pulmonary Fibrosis | 1 | 2016 | 503 | 0.400 |
Why?
|
Echocardiography | 9 | 2024 | 5041 | 0.400 |
Why?
|
Coronary Artery Disease | 8 | 2022 | 6544 | 0.390 |
Why?
|
Cardiology | 1 | 2023 | 1696 | 0.390 |
Why?
|
Eicosanoids | 2 | 2023 | 284 | 0.380 |
Why?
|
Follow-Up Studies | 23 | 2021 | 39243 | 0.380 |
Why?
|
Pyrroles | 3 | 2012 | 1120 | 0.380 |
Why?
|
Massachusetts | 9 | 2021 | 8882 | 0.380 |
Why?
|
Adiponectin | 3 | 2023 | 1120 | 0.380 |
Why?
|
Menopause, Premature | 2 | 2023 | 124 | 0.360 |
Why?
|
Metabolomics | 2 | 2020 | 1667 | 0.350 |
Why?
|
Triglycerides | 5 | 2019 | 2441 | 0.350 |
Why?
|
Heart Conduction System | 1 | 2016 | 1007 | 0.350 |
Why?
|
Exercise | 7 | 2022 | 5939 | 0.350 |
Why?
|
American Heart Association | 6 | 2023 | 1045 | 0.340 |
Why?
|
Severity of Illness Index | 6 | 2024 | 15882 | 0.340 |
Why?
|
Diastole | 5 | 2015 | 785 | 0.330 |
Why?
|
Peptide Fragments | 5 | 2024 | 5126 | 0.330 |
Why?
|
Pulsatile Flow | 1 | 2010 | 318 | 0.320 |
Why?
|
Leptin | 3 | 2023 | 1596 | 0.320 |
Why?
|
Predictive Value of Tests | 12 | 2023 | 15403 | 0.320 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2012 | 4408 | 0.310 |
Why?
|
Interleukins | 1 | 2013 | 789 | 0.310 |
Why?
|
Blood Glucose | 5 | 2018 | 6421 | 0.300 |
Why?
|
Forecasting | 2 | 2017 | 2936 | 0.300 |
Why?
|
Waist Circumference | 3 | 2024 | 934 | 0.300 |
Why?
|
Prevalence | 8 | 2024 | 15827 | 0.290 |
Why?
|
Galectins | 4 | 2019 | 293 | 0.290 |
Why?
|
HIV Infections | 9 | 2020 | 17535 | 0.290 |
Why?
|
Cause of Death | 3 | 2018 | 3715 | 0.280 |
Why?
|
Heart | 6 | 2022 | 4419 | 0.280 |
Why?
|
Women's Health | 2 | 2022 | 2081 | 0.280 |
Why?
|
Interleukin-6 | 3 | 2023 | 3227 | 0.280 |
Why?
|
Blood Pressure | 7 | 2022 | 8532 | 0.280 |
Why?
|
Prediabetic State | 1 | 2013 | 547 | 0.270 |
Why?
|
Mortality | 4 | 2021 | 2911 | 0.270 |
Why?
|
Adiposity | 3 | 2024 | 1892 | 0.270 |
Why?
|
Ventricular Remodeling | 3 | 2023 | 1276 | 0.270 |
Why?
|
Genome-Wide Association Study | 12 | 2024 | 12803 | 0.260 |
Why?
|
Echocardiography, Doppler | 3 | 2016 | 899 | 0.260 |
Why?
|
Benzazepines | 1 | 2008 | 308 | 0.260 |
Why?
|
Decision Support Techniques | 1 | 2016 | 2006 | 0.260 |
Why?
|
Polymorphism, Single Nucleotide | 6 | 2018 | 16040 | 0.250 |
Why?
|
United States | 19 | 2023 | 72920 | 0.250 |
Why?
|
Cholesterol, HDL | 3 | 2018 | 1813 | 0.250 |
Why?
|
Electronic Health Records | 1 | 2023 | 4863 | 0.250 |
Why?
|
Cohort Studies | 14 | 2021 | 41684 | 0.250 |
Why?
|
Echocardiography, Doppler, Pulsed | 2 | 2015 | 68 | 0.240 |
Why?
|
Pre-Eclampsia | 2 | 2024 | 1257 | 0.240 |
Why?
|
Natural Language Processing | 2 | 2024 | 1198 | 0.240 |
Why?
|
Mass Screening | 2 | 2024 | 5450 | 0.230 |
Why?
|
Odds Ratio | 6 | 2020 | 9657 | 0.230 |
Why?
|
Fibrosis | 3 | 2020 | 2073 | 0.230 |
Why?
|
Clinical Trials as Topic | 2 | 2024 | 8038 | 0.230 |
Why?
|
Metabolic Networks and Pathways | 2 | 2021 | 798 | 0.230 |
Why?
|
Health Status Disparities | 1 | 2016 | 1878 | 0.230 |
Why?
|
Linear Models | 4 | 2020 | 5873 | 0.230 |
Why?
|
Glomerular Filtration Rate | 2 | 2013 | 2232 | 0.220 |
Why?
|
Cross-Sectional Studies | 11 | 2024 | 26290 | 0.220 |
Why?
|
Heart Atria | 2 | 2024 | 1363 | 0.220 |
Why?
|
Insulin | 4 | 2019 | 6604 | 0.220 |
Why?
|
Logistic Models | 4 | 2021 | 13273 | 0.210 |
Why?
|
Epoxy Compounds | 1 | 2023 | 137 | 0.210 |
Why?
|
Kaplan-Meier Estimate | 4 | 2021 | 6506 | 0.210 |
Why?
|
Simvastatin | 2 | 2017 | 345 | 0.210 |
Why?
|
Linoleic Acid | 1 | 2023 | 158 | 0.200 |
Why?
|
Colorectal Neoplasms | 1 | 2022 | 6961 | 0.200 |
Why?
|
Coronary Circulation | 2 | 2024 | 1601 | 0.200 |
Why?
|
Cluster Analysis | 2 | 2023 | 2718 | 0.190 |
Why?
|
Growth Differentiation Factors | 1 | 2022 | 99 | 0.190 |
Why?
|
Multivariate Analysis | 5 | 2016 | 12061 | 0.190 |
Why?
|
Genome, Human | 2 | 2013 | 4443 | 0.190 |
Why?
|
Insulin-Secreting Cells | 3 | 2019 | 899 | 0.180 |
Why?
|
Cardiomyopathy, Hypertrophic | 2 | 2023 | 1338 | 0.180 |
Why?
|
Vascular Resistance | 1 | 2024 | 939 | 0.180 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2024 | 559 | 0.180 |
Why?
|
Signal Transduction | 3 | 2021 | 23605 | 0.170 |
Why?
|
Tunica Media | 2 | 2011 | 107 | 0.170 |
Why?
|
Complement Factor D | 1 | 2019 | 67 | 0.170 |
Why?
|
Algorithms | 1 | 2020 | 14066 | 0.170 |
Why?
|
Mitogen-Activated Protein Kinase Phosphatases | 1 | 2019 | 47 | 0.170 |
Why?
|
Quantitative Trait Loci | 3 | 2021 | 2136 | 0.170 |
Why?
|
Aged, 80 and over | 11 | 2021 | 59515 | 0.170 |
Why?
|
Complement C3a | 1 | 2019 | 64 | 0.170 |
Why?
|
Dual-Specificity Phosphatases | 1 | 2019 | 71 | 0.170 |
Why?
|
Terrorism | 1 | 2002 | 211 | 0.170 |
Why?
|
Peroxidase | 1 | 2022 | 610 | 0.160 |
Why?
|
Intra-Abdominal Fat | 1 | 2024 | 624 | 0.160 |
Why?
|
Teaching Rounds | 1 | 2023 | 280 | 0.160 |
Why?
|
Live Birth | 1 | 2023 | 516 | 0.160 |
Why?
|
Aneurysm | 1 | 2022 | 343 | 0.160 |
Why?
|
National Heart, Lung, and Blood Institute (U.S.) | 1 | 2020 | 325 | 0.150 |
Why?
|
Pulmonary Ventilation | 1 | 2020 | 375 | 0.150 |
Why?
|
Time Factors | 9 | 2020 | 40108 | 0.150 |
Why?
|
Asymptomatic Diseases | 2 | 2018 | 586 | 0.150 |
Why?
|
Antiretroviral Therapy, Highly Active | 3 | 2012 | 1899 | 0.150 |
Why?
|
Pulmonary Gas Exchange | 1 | 2020 | 389 | 0.150 |
Why?
|
Artificial Intelligence | 4 | 2024 | 2662 | 0.140 |
Why?
|
Kidney | 6 | 2023 | 7072 | 0.140 |
Why?
|
Oxygen | 3 | 2023 | 4247 | 0.140 |
Why?
|
Education | 1 | 2020 | 531 | 0.140 |
Why?
|
Life Change Events | 1 | 2002 | 956 | 0.140 |
Why?
|
Pulmonary Circulation | 1 | 2020 | 744 | 0.140 |
Why?
|
Retrospective Studies | 9 | 2023 | 81565 | 0.140 |
Why?
|
Research Report | 1 | 2020 | 367 | 0.140 |
Why?
|
Gonadal Steroid Hormones | 1 | 2021 | 706 | 0.140 |
Why?
|
Hormone Replacement Therapy | 1 | 2002 | 752 | 0.140 |
Why?
|
Spironolactone | 1 | 2020 | 415 | 0.140 |
Why?
|
Disasters | 1 | 2002 | 521 | 0.130 |
Why?
|
Patient Readmission | 2 | 2023 | 3283 | 0.130 |
Why?
|
Cardiomyopathy, Dilated | 1 | 2022 | 844 | 0.130 |
Why?
|
Age Factors | 5 | 2021 | 18386 | 0.130 |
Why?
|
Amyloidosis | 1 | 2023 | 883 | 0.130 |
Why?
|
Hormones | 1 | 2019 | 865 | 0.130 |
Why?
|
Pravastatin | 1 | 2017 | 391 | 0.130 |
Why?
|
Aortic Aneurysm, Thoracic | 1 | 2022 | 708 | 0.130 |
Why?
|
Isocitrates | 1 | 2015 | 23 | 0.120 |
Why?
|
Cardiac Output | 1 | 2018 | 838 | 0.120 |
Why?
|
Myocarditis | 1 | 2023 | 803 | 0.120 |
Why?
|
Aldosterone | 1 | 2020 | 881 | 0.120 |
Why?
|
Taurocholic Acid | 1 | 2015 | 43 | 0.120 |
Why?
|
Singapore | 1 | 2016 | 298 | 0.120 |
Why?
|
Aorta, Thoracic | 1 | 2021 | 1109 | 0.120 |
Why?
|
CD4 Lymphocyte Count | 2 | 2012 | 2586 | 0.120 |
Why?
|
Diabetes Mellitus, Type 2 | 5 | 2019 | 12235 | 0.110 |
Why?
|
Gene Deletion | 1 | 2021 | 2667 | 0.110 |
Why?
|
Independent Living | 1 | 2018 | 583 | 0.110 |
Why?
|
Reproducibility of Results | 5 | 2016 | 20137 | 0.110 |
Why?
|
Survival Rate | 4 | 2017 | 12827 | 0.110 |
Why?
|
2-Aminoadipic Acid | 1 | 2013 | 32 | 0.110 |
Why?
|
Cholesterol | 2 | 2018 | 2902 | 0.110 |
Why?
|
Viral Load | 3 | 2012 | 3386 | 0.110 |
Why?
|
Plasma | 1 | 2016 | 583 | 0.100 |
Why?
|
HIV | 1 | 2020 | 1587 | 0.100 |
Why?
|
Cell-Derived Microparticles | 1 | 2014 | 160 | 0.100 |
Why?
|
Metabolic Diseases | 1 | 2019 | 686 | 0.100 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2018 | 1239 | 0.100 |
Why?
|
Chemokine CXCL12 | 1 | 2014 | 455 | 0.100 |
Why?
|
Anti-Retroviral Agents | 2 | 2020 | 1786 | 0.100 |
Why?
|
Respiratory Insufficiency | 1 | 2020 | 1241 | 0.100 |
Why?
|
Extracorporeal Membrane Oxygenation | 1 | 2023 | 1480 | 0.100 |
Why?
|
Transcription Factor AP-1 | 1 | 2013 | 322 | 0.100 |
Why?
|
Calcinosis | 2 | 2011 | 1475 | 0.100 |
Why?
|
Neoplasms | 4 | 2023 | 22344 | 0.100 |
Why?
|
Health Status | 1 | 2005 | 4086 | 0.100 |
Why?
|
Endothelium, Vascular | 3 | 2014 | 4423 | 0.090 |
Why?
|
Hepatitis C, Chronic | 1 | 2019 | 1032 | 0.090 |
Why?
|
Kidney Function Tests | 1 | 2013 | 684 | 0.090 |
Why?
|
Heart-Assist Devices | 1 | 2022 | 1295 | 0.090 |
Why?
|
Gene Expression Profiling | 2 | 2024 | 9527 | 0.090 |
Why?
|
Life Style | 1 | 2002 | 3928 | 0.090 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2016 | 3801 | 0.090 |
Why?
|
Genetic Predisposition to Disease | 5 | 2024 | 18076 | 0.090 |
Why?
|
Health Behavior | 1 | 2022 | 2649 | 0.090 |
Why?
|
Hospital Mortality | 2 | 2022 | 5340 | 0.090 |
Why?
|
Up-Regulation | 2 | 2016 | 4133 | 0.080 |
Why?
|
Adipose Tissue | 1 | 2022 | 3315 | 0.080 |
Why?
|
Aortic Valve Stenosis | 1 | 2022 | 2022 | 0.080 |
Why?
|
Treatment Outcome | 5 | 2020 | 65219 | 0.080 |
Why?
|
Ventricular Outflow Obstruction | 1 | 2012 | 262 | 0.080 |
Why?
|
Glucose Tolerance Test | 1 | 2013 | 1180 | 0.080 |
Why?
|
Fasting | 1 | 2016 | 1606 | 0.080 |
Why?
|
Endothelium | 1 | 2012 | 768 | 0.080 |
Why?
|
Tissue Donors | 1 | 2019 | 2392 | 0.080 |
Why?
|
Case-Control Studies | 6 | 2019 | 22228 | 0.080 |
Why?
|
Morbidity | 1 | 2015 | 1753 | 0.080 |
Why?
|
Netherlands | 3 | 2020 | 2277 | 0.080 |
Why?
|
Myeloid Differentiation Factor 88 | 1 | 2013 | 582 | 0.080 |
Why?
|
Pilot Projects | 3 | 2023 | 8724 | 0.080 |
Why?
|
Dideoxynucleosides | 1 | 2009 | 135 | 0.080 |
Why?
|
Double-Blind Method | 2 | 2014 | 12426 | 0.080 |
Why?
|
Amino Acid Substitution | 1 | 2013 | 1742 | 0.080 |
Why?
|
Nifedipine | 1 | 2009 | 220 | 0.080 |
Why?
|
Mendelian Randomization Analysis | 2 | 2024 | 1038 | 0.080 |
Why?
|
Magnetic Resonance Imaging | 5 | 2024 | 36548 | 0.080 |
Why?
|
Action Potentials | 1 | 2016 | 1834 | 0.080 |
Why?
|
Registries | 2 | 2023 | 8347 | 0.080 |
Why?
|
Hospitals | 1 | 2022 | 3887 | 0.080 |
Why?
|
Vasodilation | 2 | 2009 | 969 | 0.080 |
Why?
|
HIV-Associated Lipodystrophy Syndrome | 1 | 2009 | 137 | 0.070 |
Why?
|
Data Mining | 1 | 2013 | 560 | 0.070 |
Why?
|
Potassium | 1 | 2012 | 1312 | 0.070 |
Why?
|
Population Surveillance | 1 | 2018 | 2596 | 0.070 |
Why?
|
MicroRNAs | 1 | 2023 | 3787 | 0.070 |
Why?
|
Carotid Arteries | 1 | 2011 | 932 | 0.070 |
Why?
|
Pregnancy | 3 | 2024 | 30233 | 0.070 |
Why?
|
Longevity | 1 | 2015 | 1085 | 0.070 |
Why?
|
Image Processing, Computer-Assisted | 2 | 2021 | 8924 | 0.070 |
Why?
|
Shock, Cardiogenic | 2 | 2023 | 704 | 0.070 |
Why?
|
Tunica Intima | 1 | 2009 | 455 | 0.070 |
Why?
|
Stress, Psychological | 1 | 2002 | 4527 | 0.070 |
Why?
|
Sex Distribution | 2 | 2018 | 2270 | 0.070 |
Why?
|
Blood Volume | 1 | 2008 | 544 | 0.070 |
Why?
|
Antiviral Agents | 1 | 2019 | 3068 | 0.070 |
Why?
|
Biological Specimen Banks | 2 | 2023 | 787 | 0.070 |
Why?
|
Protein Structure, Tertiary | 1 | 2013 | 3751 | 0.070 |
Why?
|
RNA, Viral | 2 | 2012 | 2868 | 0.070 |
Why?
|
Reverse Transcriptase Inhibitors | 1 | 2009 | 618 | 0.070 |
Why?
|
Lipids | 1 | 2017 | 3316 | 0.070 |
Why?
|
Calcium Channel Blockers | 1 | 2009 | 686 | 0.060 |
Why?
|
Maximum Tolerated Dose | 1 | 2008 | 895 | 0.060 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2008 | 637 | 0.060 |
Why?
|
Heart Transplantation | 1 | 2019 | 3307 | 0.060 |
Why?
|
Heart Defects, Congenital | 1 | 2022 | 4712 | 0.060 |
Why?
|
Mice, Inbred C57BL | 2 | 2021 | 22341 | 0.060 |
Why?
|
Rest | 1 | 2010 | 940 | 0.060 |
Why?
|
NF-kappa B | 1 | 2013 | 2495 | 0.060 |
Why?
|
Hypolipidemic Agents | 1 | 2009 | 609 | 0.060 |
Why?
|
Angioplasty, Balloon, Coronary | 1 | 2011 | 1721 | 0.060 |
Why?
|
Vital Capacity | 2 | 2022 | 995 | 0.060 |
Why?
|
Biomedical Research | 1 | 2020 | 3458 | 0.060 |
Why?
|
Patient Transfer | 1 | 2011 | 789 | 0.060 |
Why?
|
Endothelial Cells | 3 | 2024 | 3586 | 0.060 |
Why?
|
Hyperlipidemias | 1 | 2009 | 770 | 0.060 |
Why?
|
Aminopeptidases | 1 | 2024 | 113 | 0.060 |
Why?
|
HEK293 Cells | 1 | 2013 | 4263 | 0.060 |
Why?
|
Genetic Association Studies | 1 | 2013 | 2744 | 0.060 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2008 | 878 | 0.060 |
Why?
|
Ultrasonography | 3 | 2012 | 5988 | 0.060 |
Why?
|
Adrenomedullin | 1 | 2023 | 85 | 0.050 |
Why?
|
Models, Molecular | 1 | 2013 | 5382 | 0.050 |
Why?
|
Diet | 1 | 2021 | 8087 | 0.050 |
Why?
|
Dose-Response Relationship, Drug | 3 | 2012 | 10737 | 0.050 |
Why?
|
Body Fat Distribution | 1 | 2024 | 246 | 0.050 |
Why?
|
Carotid Artery Diseases | 1 | 2009 | 872 | 0.050 |
Why?
|
Motor Activity | 1 | 2013 | 2711 | 0.050 |
Why?
|
Atrial Function, Left | 1 | 2024 | 189 | 0.050 |
Why?
|
Magnetic Resonance Imaging, Cine | 2 | 2023 | 1093 | 0.050 |
Why?
|
Acute Disease | 2 | 2015 | 7237 | 0.050 |
Why?
|
Forced Expiratory Volume | 2 | 2022 | 1828 | 0.050 |
Why?
|
Cerebrovascular Disorders | 1 | 2009 | 1478 | 0.050 |
Why?
|
Arrhythmias, Cardiac | 1 | 2012 | 2255 | 0.050 |
Why?
|
Promoter Regions, Genetic | 1 | 2013 | 5784 | 0.050 |
Why?
|
Disease Progression | 3 | 2014 | 13616 | 0.050 |
Why?
|
Boston | 1 | 2014 | 9335 | 0.050 |
Why?
|
Magnetic Resonance Spectroscopy | 2 | 2023 | 3678 | 0.050 |
Why?
|
Myocardial Ischemia | 1 | 2012 | 2132 | 0.050 |
Why?
|
Aging | 1 | 2020 | 8723 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2011 | 10380 | 0.050 |
Why?
|
Lipid Metabolism | 1 | 2009 | 1893 | 0.040 |
Why?
|
Gene Expression | 1 | 2013 | 7582 | 0.040 |
Why?
|
Antineoplastic Agents | 1 | 2023 | 13635 | 0.040 |
Why?
|
Physical Exertion | 1 | 2023 | 666 | 0.040 |
Why?
|
Epidemiologic Studies | 1 | 2003 | 677 | 0.040 |
Why?
|
Drug Administration Schedule | 1 | 2008 | 4853 | 0.040 |
Why?
|
New York | 1 | 2002 | 880 | 0.040 |
Why?
|
Fractional Flow Reserve, Myocardial | 1 | 2024 | 346 | 0.040 |
Why?
|
Glucosides | 1 | 2024 | 532 | 0.040 |
Why?
|
Microvessels | 1 | 2024 | 590 | 0.040 |
Why?
|
Confidence Intervals | 1 | 2005 | 2915 | 0.040 |
Why?
|
Follistatin-Related Proteins | 1 | 2019 | 48 | 0.040 |
Why?
|
Microcirculation | 1 | 2024 | 1282 | 0.040 |
Why?
|
Mice | 3 | 2021 | 81839 | 0.040 |
Why?
|
Cell Dedifferentiation | 1 | 2019 | 125 | 0.040 |
Why?
|
Natriuretic Peptides | 1 | 2020 | 153 | 0.040 |
Why?
|
Comorbidity | 2 | 2023 | 10579 | 0.040 |
Why?
|
Constriction, Pathologic | 1 | 2022 | 1102 | 0.040 |
Why?
|
Death | 1 | 2023 | 686 | 0.040 |
Why?
|
Spirometry | 1 | 2022 | 929 | 0.040 |
Why?
|
Calcium | 1 | 2011 | 5770 | 0.040 |
Why?
|
Population Growth | 1 | 2018 | 50 | 0.040 |
Why?
|
Coronary Vessels | 2 | 2024 | 3094 | 0.040 |
Why?
|
Benzhydryl Compounds | 1 | 2024 | 943 | 0.040 |
Why?
|
Neovascularization, Physiologic | 1 | 2024 | 1370 | 0.040 |
Why?
|
Pyrrolidines | 1 | 2019 | 337 | 0.040 |
Why?
|
Young Adult | 4 | 2019 | 59868 | 0.040 |
Why?
|
Quinoxalines | 1 | 2019 | 296 | 0.040 |
Why?
|
Postpartum Period | 1 | 2024 | 1195 | 0.030 |
Why?
|
Aortic Aneurysm | 1 | 2021 | 649 | 0.030 |
Why?
|
Xanthines | 1 | 2016 | 121 | 0.030 |
Why?
|
Ribonucleosides | 1 | 2016 | 79 | 0.030 |
Why?
|
Educational Status | 1 | 2003 | 2510 | 0.030 |
Why?
|
Statistics as Topic | 1 | 2002 | 2351 | 0.030 |
Why?
|
Incidental Findings | 1 | 2021 | 698 | 0.030 |
Why?
|
Estrogen Replacement Therapy | 1 | 2002 | 1206 | 0.030 |
Why?
|
Animals | 4 | 2021 | 168800 | 0.030 |
Why?
|
Genomic Instability | 1 | 2020 | 716 | 0.030 |
Why?
|
Transforming Growth Factor beta | 1 | 2023 | 1996 | 0.030 |
Why?
|
Gene Expression Regulation | 1 | 2013 | 11906 | 0.030 |
Why?
|
Liver | 1 | 2011 | 7559 | 0.030 |
Why?
|
Mice, Inbred NOD | 1 | 2019 | 1837 | 0.030 |
Why?
|
Menopause | 1 | 2023 | 1659 | 0.030 |
Why?
|
Genetic Loci | 1 | 2024 | 2630 | 0.030 |
Why?
|
Aorta | 1 | 2022 | 2040 | 0.030 |
Why?
|
Diet, Mediterranean | 1 | 2021 | 746 | 0.030 |
Why?
|
Waiting Lists | 1 | 2019 | 779 | 0.030 |
Why?
|
Benzimidazoles | 1 | 2019 | 862 | 0.030 |
Why?
|
Cholesterol Esters | 1 | 2013 | 68 | 0.030 |
Why?
|
Anti-HIV Agents | 1 | 2009 | 4561 | 0.030 |
Why?
|
Postmenopause | 1 | 2002 | 2517 | 0.030 |
Why?
|
Drug Combinations | 1 | 2019 | 2076 | 0.030 |
Why?
|
Smoking | 2 | 2014 | 9082 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 1 | 2016 | 20700 | 0.030 |
Why?
|
Transaminases | 1 | 2013 | 199 | 0.030 |
Why?
|
Tissue Culture Techniques | 1 | 2013 | 286 | 0.030 |
Why?
|
Hepacivirus | 1 | 2019 | 1343 | 0.020 |
Why?
|
Practice Guidelines as Topic | 1 | 2009 | 7424 | 0.020 |
Why?
|
Bayes Theorem | 1 | 2020 | 2353 | 0.020 |
Why?
|
Mutation | 1 | 2016 | 30209 | 0.020 |
Why?
|
Chromatography, Liquid | 1 | 2015 | 992 | 0.020 |
Why?
|
Feasibility Studies | 2 | 2015 | 5300 | 0.020 |
Why?
|
Wound Healing | 1 | 2022 | 2795 | 0.020 |
Why?
|
Hyperglycemia | 1 | 2019 | 1389 | 0.020 |
Why?
|
Risk | 2 | 2013 | 9599 | 0.020 |
Why?
|
Adolescent | 2 | 2018 | 88819 | 0.020 |
Why?
|
Chromosome Mapping | 1 | 2018 | 4617 | 0.020 |
Why?
|
Cost-Benefit Analysis | 1 | 2023 | 5531 | 0.020 |
Why?
|
Neovascularization, Pathologic | 1 | 2020 | 2627 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2016 | 3432 | 0.020 |
Why?
|
Sulfonamides | 1 | 2019 | 1980 | 0.020 |
Why?
|
Gene Frequency | 1 | 2016 | 3623 | 0.020 |
Why?
|
Cells, Cultured | 1 | 2024 | 18967 | 0.020 |
Why?
|
Research Design | 1 | 2005 | 6206 | 0.020 |
Why?
|
Organ Specificity | 1 | 2013 | 1966 | 0.020 |
Why?
|
Alcohol Drinking | 1 | 2021 | 4044 | 0.020 |
Why?
|
HIV-1 | 2 | 2019 | 6948 | 0.020 |
Why?
|
Serum Albumin | 1 | 2011 | 673 | 0.020 |
Why?
|
Mass Spectrometry | 1 | 2015 | 2195 | 0.020 |
Why?
|
Glucose | 1 | 2019 | 4335 | 0.020 |
Why?
|
Positron-Emission Tomography | 1 | 2024 | 6545 | 0.020 |
Why?
|
Chronic Disease | 1 | 2021 | 9354 | 0.020 |
Why?
|
Creatinine | 1 | 2011 | 1916 | 0.020 |
Why?
|
Reference Values | 1 | 2012 | 4909 | 0.020 |
Why?
|
Hemoglobins | 1 | 2011 | 1531 | 0.020 |
Why?
|
Vasodilator Agents | 1 | 2009 | 988 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2020 | 10433 | 0.010 |
Why?
|
Single-Blind Method | 1 | 2008 | 1588 | 0.010 |
Why?
|
Antigens, CD | 1 | 2014 | 4025 | 0.010 |
Why?
|
Regression Analysis | 1 | 2013 | 6324 | 0.010 |
Why?
|
Antihypertensive Agents | 1 | 2012 | 2028 | 0.010 |
Why?
|
Heart Arrest | 1 | 2012 | 1516 | 0.010 |
Why?
|
Survival Analysis | 1 | 2015 | 10087 | 0.010 |
Why?
|
Homeostasis | 1 | 2013 | 3338 | 0.010 |
Why?
|
Equipment Design | 1 | 2008 | 3489 | 0.010 |
Why?
|
Oxidative Stress | 1 | 2011 | 3140 | 0.010 |
Why?
|
Cell Line | 1 | 2013 | 15546 | 0.010 |
Why?
|
Point-of-Care Systems | 1 | 2008 | 1218 | 0.010 |
Why?
|
Internship and Residency | 1 | 2008 | 5946 | 0.000 |
Why?
|